|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the present study suggested that NOB1 depletion may inhibit osteosarcoma development by increasing E-cadherin and β-catenin expression and, for the first time, indicated the potential of NOB1 as a target in osteosarcoma treatment.
|
24714960 |
2014 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the precise role of T cell factors/lymphoid enhancer-binding factor (TCFs/LEF) family members, which are the major binding complex of β-catenin, in OS is poorly understood.
|
31595984 |
2020 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings indicate that XRCC6 exerts tumor-promoting effects for OS through β-catenin/Wnt signaling pathway.
|
27455247 |
2016 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we revealed that silybin inhibited OS cell viability by altering the protein levels of β-catenin and Runt-related transcription factor 2 (RUNX2) as determined by western blot and immunocytochemistry (ICC).
|
29068478 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of subsequent western blot and reverse transcription‑quantitative polymerase chain reaction analyses revealed that the protein levels of β‑catenin and cyclin D1 were markedly upregulated in the fluorescence‑activated cell sorted osteosarcoma SP cells.
|
26134785 |
2015 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway.
|
30816476 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed protein levels and nuclear localization of β-catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B).
|
28370561 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also investigated changes in expression, phosphorylation and co-transcriptional activity of β-catenin in osteosarcoma cells following GSK-3β inhibition.
|
27780915 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPI induced inhibition of osteosarcoma cell viability was abolished upon addition of GSK-3β specific inhibitor, CHIR99021, while PPI induced inhibition of osteosarcoma cell viability and migration were potentiated by β-catenin silencing.
|
28790389 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that E2 upregulates the expression of <i>NFKB1</i>, <i>ATF7IP</i>, and <i>HDAC5</i>, all of which are involved in the regulation of gene expression and transcription, but downregulates that of <i>TCF7L2</i>, <i>ALCAM</i>, and <i>AKT</i>, which are involved in Wnt receptor signaling through β-catenin and morphogenesis in U2OS osteosarcoma cells.
|
28744146 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Next, we found lncSox4 regulation of osteosarcoma is involved in β-catenin, and overexpression of lncSox4 could stable β-catenin expression.
|
29441981 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that miR-135b mediates the constitutive activation of Wnt/β-catenin and Notch signaling, and that the inhibition of miR-135b is a novel strategy to inhibit tumor metastasis and prevent CSC-induced recurrence in OS.
|
28918013 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also showed that SALL4 knockdown decreased the protein expression of Wnt3a and β-catenin in osteosarcoma cells.
|
27983924 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified that metastatic lung OS cell lines (n = 2) exhibited increased stem cell signatures, including enhanced concomitant aldehyde dehydrogenase (ALDH1) and β-catenin expression and downstream activity, which were suppressed by Tegavivint (ALDH1: control group, mean relative mRNA expression = 1.00, 95% confidence interval [CI] = 0.68 to 1.22 vs Tegavivint group, mean = 0.011, 95% CI = 0.0012 to 0.056, P < .001; β-catenin: control group, mean relative mRNA expression = 1.00, 95% CI = 0.71 to 1.36 vs Tegavivint group, mean = 0.45, 95% CI = 0.36 to 0.52, P < .001).
|
30793158 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, the expression level of β-catenin protein correlated with the invasiveness of OS, as evidenced by more intensive β-catenin immunoreactivity in higher grade OS samples.
|
23291185 |
2013 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the wild-type β-catenin plasmid in osteosarcoma cells resulted in enhanced cell invasiveness but this effect was significantly overcome by curcumin.
|
19730790 |
2010 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that CD151 knockdown inhibits the expression of MMP9 through the GSK-3β/β‑catenin pathway and also inhibits OS migration and invasion in vitro and metastasis in vivo in highly metastatic OS.
|
26707073 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AWPPH enhances FZD7-mediated activation of Wnt/β-catenin by sponging miR-93-3p to promote OS progression.
|
31092328 |
2019 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemical staining and western blot analysis, the degree of the expression of BAMBI and β-catenin was significantly higher in osteosarcoma specimens compared with normal tissues.
|
23807684 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that targeting the Wnt/β-catenin pathway can eliminate CSCs populations in osteosarcoma.
|
29126913 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of β-catenin plays a role in potentiating expression and downstream anti-apoptotic factor Bcl-2, and in enhancing ADM resistance of osteosarcoma U2OS cells.
|
28770967 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our study indicated that macrophage-derived CCL18 promotes OS proliferation and metastasis via the EP300/UCA1/Wnt/β-catenin pathway and that CCL18 may be used as a prognostic marker and therapeutic target of OS.
|
30426155 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
And β-catenin may be a potential therapeutic target as well as a significant prognostic marker for osteosarcoma patients in clinic.
|
29497056 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found increased protein levels of endogenous active-β-catenin in five human osteosarcoma cell lines.
|
30613366 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis.
|
29852168 |
2018 |